What type of study is this?

This is a Human Clinical Trial study (also classified as: Validation Study).

December 8, 2025BloodOpen Access

Validation of the international working group (IWG) 2023 criteria for clinical benefit in higher risk Myelodysplastic Syndromes (HR-MDS) using a large, international, randomized Phase 3 clinical trial dataset

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial shows the prognostic impact of IWG 2023 criteria on survival in HR-MDS patients, suggesting azacitidine improves clinical outcomes.

To validate the IWG 2023 criteria for clinical benefit in higher risk myelodysplastic syndromes using a Phase 3 clinical trial dataset.
Examined data from the PANTHER trial comparing azacitidine versus azacitidine alone in HR-MDS patients.
Assessed IWG 2023 responses using blood count and bone marrow blast analysis.
Calculated overall survival analyzing the association of IWG 2023 criteria with survival outcomes.
Of 163 patients, 51% achieved clinical complete response according to IWG 2023 criteria.
Improved overall survival observed in patients achieving composite complete response plus partial remission.
Median overall survival was 18 months, with significant differences based on response categories.

Murdock et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial shows the prognostic impact of IWG 2023 criteria on survival in HR-MDS patients, suggesting azacitidine improves clinical outcomes.